Gracell Biotechnologies Inc. is a biotechnology business based in the US. Gracell Biotechnologies shares (GRCL) are listed on the NASDAQ and all prices are listed in US Dollars. Gracell Biotechnologies employs 348 staff and has a trailing 12-month revenue of around $366,000.
How to buy shares in Gracell Biotechnologies
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GRCL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Gracell Biotechnologies stock price (NASDAQ: GRCL)Use our graph to track the performance of GRCL stocks over time.
Gracell Biotechnologies shares at a glance
|Latest market close||$3.27|
|52-week range||$1.68 - $15.00|
|50-day moving average||$2.96|
|200-day moving average||$3.47|
|Wall St. target price||$14.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.13|
Buy Gracell Biotechnologies shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Gracell Biotechnologies stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gracell Biotechnologies price performance over time
|1 week (2022-09-27)||28.74%|
|1 month (2022-09-02)||36.25%|
|3 months (2022-07-01)||-35.88%|
|6 months (2022-04-04)||23.40%|
|1 year (2021-10-04)||-77.00%|
|2 years (2020-09-30)||N/A|
|3 years (2019-09-30)||N/A|
|5 years (2017-09-30)||N/A|
Gracell Biotechnologies financials
|Gross profit TTM||$366,000|
|Return on assets TTM||-17.19%|
|Return on equity TTM||-30.53%|
|Market capitalisation||$176 million|
TTM: trailing 12 months
Gracell Biotechnologies share dividends
We're not expecting Gracell Biotechnologies to pay a dividend over the next 12 months.
You may also wish to consider:
- Amgen (AMGN.US) (3.42% forward annual dividend yield)
Gracell Biotechnologies overview
Gracell Biotechnologies Inc. , a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China. .
Gracell Biotechnologies in the news
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
Frequently asked questionsWhat percentage of Gracell Biotechnologies is owned by insiders or institutions?
Currently 7.889% of Gracell Biotechnologies shares are held by insiders and 47.687% by institutions. How many people work for Gracell Biotechnologies?
Latest data suggests 348 work at Gracell Biotechnologies. When does the fiscal year end for Gracell Biotechnologies?
Gracell Biotechnologies's fiscal year ends in December. Where is Gracell Biotechnologies based?
Gracell Biotechnologies's address is: Building 12, Block B, Suzhou, China, 215123 What is Gracell Biotechnologies's ISIN number?
Gracell Biotechnologies's international securities identification number is: US38406L1035
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert